“Management of acute pain remains a significant clinical problem. In preclinical studies, CB2 cannabinoid receptor-selective agonists inhibit nociception without producing central nervous system side effects.
The experiments reported here further test the hypothesis that CB2 receptor activation inhibits nociception…
The CB2 receptor-selective agonist produces antinociceptive… activation of CB2 receptors results in antinociception…
…confirm the potential therapeutic relevance of CB2 cannabinoid receptors for the treatment of acute pain.”